LOG IN
SIGN UP
MARKET
SLRX
SLRX
Salarius Pharmaceuticals Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.1803
-0.0023
-1.26%
After Hours: 0.1840 +0.0037 +2.05% 18:20 05/26 EDT
OPEN
0.1801
PREV CLOSE
0.1826
HIGH
0.1844
LOW
0.1712
VOLUME
574.05K
TURNOVER
0
52 WEEK HIGH
1.490
52 WEEK LOW
0.1599
MARKET CAP
10.12M
P/E (TTM)
-0.4809
1D
5D
1M
3M
1Y
5Y
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Benzinga · 05/19 16:31
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) shares rose 20.9% to $0.70 in pre-market trading after dropping 12% on Wednesday. Acorda Therapeutics recently posted a Q1 loss of $1.66 per share.
Benzinga · 05/19 10:44
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers,...
GlobeNewswire · 05/18 20:10
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
23 Stocks Moving in Friday's Pre-Market Session
Gainers OTR Acquisition Corp. (NASDAQ: OTRA) rose 88.7% to $18.21 in pre-market trading after filing on Thursday showed shareholders approved merger with Comera Life Sciences.
Benzinga · 05/13 11:52
Salarius Pharmaceuticals: Q1 Earnings Insights
Salarius Pharmaceuticals (NASDAQ:SLRX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 22:39
Salarius Pharmaceuticals Q1 EPS $(0.13) Misses $(0.09) Estimate
Salarius Pharmaceuticals (NASDAQ:SLRX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 116.67 percent decrease over losses of $(0.06) per
Benzinga · 05/12 21:36
Salarius Pharmaceuticals GAAP EPS of -$0.13 misses by $0.04
Salarius Pharmaceuticals press release (NASDAQ:SLRX): Q1 GAAP EPS of -$0.13 misses by $0.04. Co recorded no revenue for Q1 vs. revenue of $1.3M last year. As of March 31, 2022,
Seekingalpha · 05/12 20:13
No Data
Learn about the latest financial forecast of SLRX. Analyze the recent business situations of Salarius Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 1 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SLRX stock price target is 4.250 with a high estimate of 5.00 and a low estimate of 3.500.
Current 0.1803
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Institutional Holdings
Institutions: 36
Institutional Holdings: 5.32M
% Owned: 9.48%
Shares Outstanding: 56.12M
TypeInstitutionsShares
Increased
8
468.87K
New
6
207.74K
Decreased
6
769.91K
Sold Out
5
1.31M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Director
William McVicar
President/Chief Executive Officer/Director
David Arthur
Chief Financial Officer/Executive Vice President - Finance
Mark Rosenblum
Senior Vice President
Nadeem Mirza
Lead Director/Independent Director
Paul Lammers
Director
Bruce Mccreedy
Independent Director
Tess Burleson
Independent Director
Arnold Hanish
Independent Director
Jonathan Lieber
No Data
No Data
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing epigenetic-based cancer treatments. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead product candidate, Seclidemstat (SP-2577), is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1). SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression. The Company is also developing SP-2577 for several cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.